CTOs on the Move

Scioto Biosciences

www.sciotobiosciences.com

 
Scioto Biosciences is a preclinical stage biotech company dedicated to innovative research and discovery in the field of microbiome therapeutics.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.sciotobiosciences.com
  • Noyes Pavilion, 5th Floor Suite E504, 1800 N. Capitol Ave
    Indianapolis, IN USA 46202
  • Phone: 866.672.4686

Executives

Name Title Contact Details

Funding

Scioto Biosciences raised $26.5M on 08/10/2020

Similar Companies

Avantgen Inc

Avantgen Inc is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ADMA Biologics

ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and com...

Pathogen Detection Systems

Pathogen Detection Systems, Inc. is a Thunder Bay, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Genemed Synthesis

Genemed Synthesis, Inc. is a San Antonio, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Be Biopharma

Be Biopharma is a leader in developing B cells as medicines, treating disease with the human body`s native protein factories. We precisely engineer B cells to harness their intrinsic drug-like properties – remarkable protein production, selective tissue targeting, and fine control of their cellular environment – to forge a new category of cell therapy. These medicines are designed to be durable, allogeneic, re-dosable, and administered without toxic conditioning, creating new avenues to halt or reverse severe diseases like cancer, autoimmune conditions, and enzyme deficiency. Founded by Longwood Fund and B cell engineering pioneers David Rawlings, M.D., and Richard James, Ph.D., Be Biopharma is re-imagining medicine based on the power of B cell therapy. Be Bio was founded in October 2020 by Longwood Fund with a $52 million Series A investment led by Atlas Ventures and RA Capital, joined by Alta Partners and Takeda Ventures.